Publicaciones en las que colabora con Jesús Egido de los Ríos (55)

2021

  1. Mcp-1 predicts recurrent cardiovascular events in patients with persistent inflammation

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-13

2020

  1. CD163 deficiency increases foam cell formation and plaque progression in atherosclerotic mice

    FASEB Journal, Vol. 34, Núm. 11, pp. 14960-14976

2018

  1. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease

    Atherosclerosis, Vol. 270, pp. 13-20

2017

  1. Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway

    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 10, pp. 207-222

  2. Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease

    Atherosclerosis, Vol. 260, pp. 130-137

  3. TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice

    Scientific Reports, Vol. 7

2015

  1. Targeting metabolic disturbance in the diabetic heart

    Cardiovascular Diabetology, Vol. 14, Núm. 1

2013

  1. Alteration of energy substrates and ROS production in diabetic cardiomyopathy

    Mediators of Inflammation, Vol. 2013

  2. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes

    Cardiovascular Diabetology, Vol. 12, Núm. 1

  3. Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

    PLoS ONE, Vol. 8, Núm. 10

  4. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1832, Núm. 10, pp. 1744-1755

2012

  1. Angiotensin II contributes to renal fibrosis independently of notch pathway activation

    PLoS ONE, Vol. 7, Núm. 7

  2. HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II

    Laboratory Investigation, Vol. 92, Núm. 1, pp. 32-45

  3. Proteome changes in the myocardium of experimental chronic diabetes and hypertension. Role of PPARα in the associated hypertrophy

    Journal of Proteomics, Vol. 75, Núm. 6, pp. 1816-1829

2011

  1. Potential role of nuclear factor κb in diabetic cardiomyopathy

    Mediators of Inflammation, Vol. 2011

2010

  1. Obstructive renal injury: From fluid mechanics to molecular cell biology

    Open Access Journal of Urology, Vol. 2, Núm. 1, pp. 41-55

  2. Regulation of vascular and renal cells by common mediators in health and disease: Role of the renin-angiotensin system in the pathophysiology of hypertension and cardiovascular disease

    Cardiorenal Syndrome: Mechanisms, Risk and Treatment (Springer Milan), pp. 49-63

  3. Statins inhibit angiotensin II/smad pathway and related vascular fibrosis, by a TGF-β-independent process

    PLoS ONE, Vol. 5, Núm. 11

  4. TNF superfamily: A growing saga of kidney injury modulators

    Mediators of Inflammation, Vol. 2010

2009

  1. A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury

    PLoS ONE, Vol. 4, Núm. 8